Education
About Us
Working with TipRanks
Follow Us
Inspira Technologies Oxy BHN (IINN)
NASDAQ:IINN
IINN Stock Chart & Stats
$0.96
-$0.05(-4.95%)
At close: 4:00 PM EST
$0.96
-$0.05(-4.95%)
Day’s Range― - ―
52-Week Range$0.40 - $1.65
Previous CloseN/A
Volume61.41K
Average Volume (3M)330.47K
Market Cap
$26.57M
Enterprise Value$13.30M
Total Cash (Recent Filing)$2.13M
Total Debt (Recent Filing)$640.00K
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Apr 01, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding43,271,835
10 Day Avg. Volume227,613
30 Day Avg. Volume330,466
Financial Highlights & Ratios
PEG Ratio17.10
Price to Book (P/B)4.37
Price to Sales (P/S)0.00
P/FCF Ratio-1.98
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue46.02
Enterprise Value/Gross Profit6.65K
Enterprise Value/Ebitda-1.86
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.11
Revenue Forecast (FY)$48.00M
Bulls Say, Bears Say
Bulls Say
Standalone HYLA Validation Expands TAMDecoupling HYLA from Inspira’s life-support hardware creates a standalone product that can plug into existing OR/ICU workflows, opening a much larger $50B addressable market. The design enables recurring high-margin sensor disposables and software upgrades, improving long-term revenue visibility and gross-margin potential.
Clinical Validation Of ART100 At Top U.S. CenterMoving from pilot evaluation to budgeted procurement at a leading academic center materially de-risks clinical adoption. This institutional endorsement supports broader hospital purchasing pathways, shortens procurement cycles elsewhere, and strengthens the company’s commercial positioning for scaling installations and recurring consumable sales.
Patent Protection For Convertible Cannula DeviceSecuring patent rights in Japan (and prior U.S. protection) creates durable intellectual-property barriers in two major device markets. The patented cannula supports unique product differentiation, protects prospective disposable revenue streams, and raises the cost for competitors to replicate the device architecture over the medium term.
Bears Say
Persistent Unprofitable Core OperationsThe company’s core products have not yet generated positive gross margins, producing consistent net losses and undermining internal funding sources. Negative gross profit means unit economics are adverse; absent quick margin improvement, the business will remain reliant on external capital, limiting sustainable R&D and commercial scale.
Significant Cash Burn And Weakening Balance SheetLarge operating cash outflows and declining equity indicate recurring financing needs and reduced financial flexibility. Moderate leverage and a materially weakened balance sheet heighten funding sensitivity, increasing the probability of dilution or constrained investment in commercial execution over the coming months.
Acquisition Plan Risks Dilution And DistractionPursuing a sizable, equity-funded acquisition shifts focus into diagnostics, requires major equity issuance and contingent rights, and draws management and capital away from respiratory commercialization. Integration and regulatory execution risk could slow ART/HYLA rollouts and strain limited cash and organizational bandwidth over the medium term.
Inspira Technologies Oxy BHN News
IINN FAQ
What was Inspira Technologies Oxy BHN’s price range in the past 12 months?
Inspira Technologies Oxy BHN lowest stock price was $0.40 and its highest was $1.65 in the past 12 months.
What is Inspira Technologies Oxy BHN’s market cap?
Inspira Technologies Oxy BHN’s market cap is $26.57M.
When is Inspira Technologies Oxy BHN’s upcoming earnings report date?
Inspira Technologies Oxy BHN’s upcoming earnings report date is Apr 01, 2026 which is in 27 days.
How were Inspira Technologies Oxy BHN’s earnings last quarter?
Currently, no data Available
Is Inspira Technologies Oxy BHN overvalued?
According to Wall Street analysts Inspira Technologies Oxy BHN’s price is currently Overvalued.
Does Inspira Technologies Oxy BHN pay dividends?
Inspira Technologies Oxy BHN does not currently pay dividends.
What is Inspira Technologies Oxy BHN’s EPS estimate?
Inspira Technologies Oxy BHN’s EPS estimate is -0.2.
How many shares outstanding does Inspira Technologies Oxy BHN have?
Inspira Technologies Oxy BHN has 43,271,835 shares outstanding.
What happened to Inspira Technologies Oxy BHN’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Inspira Technologies Oxy BHN?
Currently, no hedge funds are holding shares in IINN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inspira Technologies Oxy BHN Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
Inspira Technologies Oxy BHN
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
4.46% Other Institutional Investors
95.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---